Hepatitis B vaccination and the rate of seroconversion in high risk contacts.
J Indian Med Assoc
;
1993 Nov; 91(11): 281-2, 285
Article
in English
| IMSEAR
| ID: sea-102106
ABSTRACT
Twenty-seven employees of a blood transfusion centre, Calcutta were vaccinated with hepatitis B vaccine (recombinant DNA technology), 20 micrograms/1 ml intramuscularly on 0, 8, 32 weeks interval. The seroconversion rate at 8, 32, 40 weeks were 29.6%, 55.5% and 100% respectively. The recombinant hepatitis B vaccine is acceptable and safe. The seroconversion rate is comparable to plasma derived hepatitis B vaccine.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Blood Banks
/
Blood Donors
/
Female
/
Humans
/
Male
/
Vaccines, Synthetic
/
Mass Screening
/
Risk Factors
/
Vaccination
/
Health Personnel
Type of study:
Etiology study
/
Prognostic study
/
Risk factors
/
Screening study
Language:
English
Journal:
J Indian Med Assoc
Year:
1993
Type:
Article
Similar
MEDLINE
...
LILACS
LIS